|
The effect of empagliflozin on doxorubicin-induced cardiotoxicity in breast cancer model: Is the drug effective on ERK/MAPK pathway?
|
Maryam Kahyaei-Aghdam   , Mina Islambulchilar , Hale Vaez |
|
|
|
Abstract: (274 Views) |
Introduction: An increasing number of people are diagnosed with breast cancer each year, making it one of the main causes of mortality worldwide. Chemotherapy is one of the most important cancer treatment approaches, and anthracyclines are widely used. However, many complications can occur in therapy with these medications, such as cardiac toxicity. In this study, we aimed to evaluate the possible effect of empagliflozine on doxorubicin-induced cardiotoxicity molecular pathway.
Methods and Materials: In this study, a total of 30 mice were divided into 5 groups (n=6). Negative control received saline and in all other groups, tumor was induced by using 4T1 cell line injected directly in breast pads. Positive control group received no treatment, while others received empagliflozine (10 mg/kg, orally), doxorubicin (2.17 mg/kg, Intraperiotenelly), Empagliflozine (10 mg/kg, orally) + Doxorubicin (2.17 mg/kg, Intraperiotenelly) respectively for 10 consecutive days. Histopathological examination and CPK level were applied to detect heart injury. Reactive oxygen level was determined using DCF staining method and TNF-α and NF-κB level were detected using ELISA teqnique.
Results: The result showed that CPK serum level increased in the doxorubicin group while it reduced in both of empagliflozine treated groups. Doxorubicin increased ROS generation level whereas decreased it significantly in empagliflozine treated groups. ELISA test result also shows significant low level of TNF-α and NF-κB in empagliflozin therapy.
Conclusion: Empagliflozine has a potential to be an adjunct treatment of breast cancer and shows cardioprotectivity against doxorubicine induced injuries which can be related to anti-inflammatory effect of empagliflozine through suppression of ROS and ERK pathway.
|
|
| Keywords: Cardiotoxicity, Empagliflozine, Doxorubicin, Breast cancer, ERK pathway |
|
|
Full-Text [PDF 338 kb]
(35 Downloads)
|
Type of Study: Research |
Subject:
General
Received: 2024/01/16 | Accepted: 2023/08/23 | Published: 2023/08/23
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
